Dr. Christopher Barbieri was interviewed as a co-senior author on new prostate cancer research from Weill Cornell Medicine & colleagues, regarding the interpretation of PSA levels in patients with the SPOP prostate cancer subtype.
"These findings are counterintuitive," said co-senior author Dr. Christopher Barbieri, an assistant professor of urology at Weill Cornell Medicine. "In general, if your PSA is higher, the cancer is more dangerous. However, this study found that tumors associated with a high PSA and SPOP mutations were less dangerous."
Christopher Barbieri, M.D., Ph.D., Assistant Professor in Urology and in Cell & Developmental Biology at Weill Cornell Medicine, was interviewed by the Prostate Cancer Foundation on active surveillance for prostate cancer patients. He addresses many of the common questions that patients and providers ask regarding eligibility for active surveillance and treatment protocol.
To make an appointment with NYC urologist and prostate cancer specialist Dr. Christopher Barbieri, please call our office at (212) 746-5562.
For other inquires and additional providers specializing in prostate cancer care at Weill Cornell Medicine in New York City, please call our office at (646) 962-9600.
To make an appointment with Dr. Christopher Barbieri at Weill Cornell Medicine Urology in New York City, please call our office at (212) 746-5562.
A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches.
Dr. Christopher Barbieri speaks at an US TOO prostate cancer educational seminar at Weill Cornell Medicine to discuss the role of genomics in the identification and treatment of specific subtypes of prostate cancer, precision medicine tactics, as well as emerging therapies.